SMYD2 Antibody

What is SMYD2 and why is it important in research?

SMYD2 is a member of the SMYD family of protein methyltransferases that contains a conserved catalytic SET domain split into two parts by a MYND domain/zinc finger motif. This structure facilitates protein-protein interactions . SMYD2 functions as a lysine methyltransferase that can modify both histone and non-histone proteins. It localizes to both the cytoplasm and nucleus and is highly expressed in adult mouse heart, brain, liver, kidney, thymus, and ovary, as well as in developing mouse embryos .

SMYD2 has multiple important functions:

• Transcriptional regulation through methylation of histone H3K36 (repression) and H3K4 (activation)

• Methylation of non-histone proteins including p53 at Lys370, which represses p53-mediated transcriptional activation and apoptosis

• Key roles in cardiac development, tumorigenesis, immune response regulation, and vascular smooth muscle cell homeostasis

What should researchers consider when selecting a SMYD2 antibody?

When selecting a SMYD2 antibody, researchers should consider:

• Antibody type: Polyclonal antibodies like the Thermo Fisher SMYD2 Polyclonal Antibody (Catalog Number: A16635) offer good sensitivity but may have batch-to-batch variation, while monoclonal antibodies provide better specificity and reproducibility .

• Species reactivity: Confirm cross-reactivity with your experimental species. For example, the Thermo Fisher SMYD2 Polyclonal Antibody reacts with Human, Mouse, Rat, and Monkey SMYD2 , while Cell Signaling Technology's antibody (#4251) cross-reacts with human, mouse, rat, and monkey samples .

• Application compatibility: Verify the antibody has been validated for your specific application (Western blot, immunoprecipitation, immunofluorescence, ChIP, etc.) .

• Immunogen information: Understanding the epitope region helps predict potential cross-reactivity or interference with specific domains. The Thermo Fisher antibody uses a synthetic peptide corresponding to human SMYD2 protein as its immunogen .

What are the optimal protocols for Western blotting with SMYD2 antibodies?

For optimal Western blotting with SMYD2 antibodies:

• Sample preparation:

  • Extract proteins from cells using a lysis buffer containing protease inhibitors

  • Include phosphatase inhibitors if studying SMYD2 phosphorylation status

• Gel electrophoresis and transfer:

  • Use 12.5% SDS-PAGE for optimal separation of SMYD2 (49 kDa)

  • Transfer to PVDF or nitrocellulose membranes at 100V for 1 hour or 30V overnight

• Antibody incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Incubate with primary SMYD2 antibody at 1:1000 dilution

  • Use appropriate HRP-conjugated secondary antibodies (typically anti-rabbit for SMYD2 polyclonal antibodies)

• Detection considerations:

  • Expect a band at approximately 49 kDa for SMYD2

  • Use cell extracts from various cell lines as positive controls, as shown in Figure 1 of the Thermo Fisher antibody datasheet

How should researchers optimize immunofluorescence staining with SMYD2 antibodies?

For optimal immunofluorescence staining:

• Cell preparation and fixation:

  • Seed VSMCs on glass coverslips at a density of 10³ cells/cm²

  • Fix and permeabilize cells in 75% acetone in ethanol for 5 min

  • Alternative fixation: 4% paraformaldehyde for 10 minutes followed by 0.1% Triton X-100 for permeabilization

• Blocking and antibody incubation:

  • Block with 10% goat serum for 1 hour

  • Incubate overnight with primary SMYD2 antibody (Cell Signaling #9734)

  • Wash 3 times with PBS

  • Incubate with Alexa Fluor 488 or 568-conjugated secondary antibodies (1:400 dilution)

• Counterstaining and imaging:

  • Counter-stain with DAPI (1:10,000 dilution)

  • Mount with appropriate mounting medium

  • Capture images using a fluorescence microscope

• Expected pattern:

  • SMYD2 should be detected in both nuclear and cytoplasmic compartments, with expression patterns varying by cell type

How can researchers use SMYD2 antibodies in ChIP experiments to study its epigenetic functions?

SMYD2 methylates H3K36 and H3K4, making ChIP experiments crucial for studying its epigenetic functions:

• ChIP protocol optimization:

  • Use formaldehyde crosslinking (1% for 10 minutes at room temperature)

  • Sonicate chromatin to fragments of 200-500 bp

  • Immunoprecipitate with 2-5 μg of SMYD2 antibody

  • Include appropriate controls (IgG control, input sample)

• Target identification strategy:

  • Perform ChIP-qPCR to examine SMYD2 binding at specific promoters, such as those of the TNF and IL6 genes

  • ChIP-seq can identify genome-wide SMYD2 binding sites and correlate with H3K36me2 and H3K4me marks

• Data interpretation:

  • In macrophages, SMYD2 specifically facilitates H3K36 dimethylation at Tnf and Il6 promoters to suppress their transcription

  • SMYD2 can recruit the Sin3A repressor complex to target genes, leading to transcriptional repression

What approaches can be used to study SMYD2-mediated protein methylation of non-histone targets?

To study SMYD2-mediated methylation of non-histone targets:

• In vitro methylation assays:

  • Incubate recombinant SMYD2 (wild-type or catalytically inactive F184A mutant) with potential substrates and S-adenosyl methionine

  • Detect methylation through:

    • Western blotting with methyl-lysine-specific antibodies

    • Radioactive assays using ³H-labeled SAM

    • Mass spectrometry for site identification

• Methylome analysis:

  • Use 3×MBT pulldowns combined with MS-based quantitative proteomics to identify methylated proteins

  • Compare methylation patterns between samples treated with wild-type SMYD2 versus catalytic dead SMYD2 F184A mutant

  • This approach identified 25 proteins specifically enriched in cell extracts incubated with enzymatically active SMYD2

• Site-specific methylation detection:

  • Generate site-specific methyl-lysine antibodies for known targets (e.g., p53K370me)

  • Use point mutations at methylation sites (e.g., K370R in p53) to confirm specificity

  • Combine with SMYD2 overexpression or knockdown studies

How can CRISPR/Cas9 technology be integrated with SMYD2 antibody applications?

Integrating CRISPR/Cas9 with SMYD2 antibody applications:

• SMYD2 knockout generation:

  • Design sgRNAs targeting Smyd2 using online tools (e.g., http://crispr.mit.edu/)

  • Clone sgRNAs into pSpCas9(BB)-2A-Puro plasmid (pX459)

  • Transfect cells and select with puromycin

  • Verify knockout efficiency by Western blot using SMYD2 antibodies

• Domain-specific functional studies:

  • Create precise mutations in SMYD2 functional domains (SET domain, MYND domain)

  • Use SMYD2 antibodies to confirm expression of mutant proteins

  • Study impact on methyltransferase activity and protein-protein interactions

• Validation strategy:

  • The specificity of observed phenotypes can be confirmed by rescue experiments with wild-type SMYD2

  • Use site-specific mutants (Smyd2Y240A, Smyd2ΔNHSC, Smyd2ΔET, and Smyd2ΔGED) that lack methyltransferase activity to determine if effects are dependent on enzymatic function

Why might researchers observe inconsistent results with SMYD2 antibodies in different cell types?

Inconsistent results with SMYD2 antibodies may occur due to:

• Variable expression levels:

  • SMYD2 expression varies significantly across tissues and developmental stages

  • It is highly expressed in adult mouse heart, brain, liver, kidney, thymus, and ovary

  • During murine hematopoiesis, Smyd2 is expressed at highest levels in Pluripotent (HSC, MPP) and Multipotent (CMP, PGMP, and GMLP) Progenitors

• Context-dependent protein interactions:

  • SMYD2 interacts with different protein complexes in different cellular contexts

  • In the absence of HSP90α, SMYD2 dimethylates H3K36, but in the presence of HSP90α, it methylates H3K4

  • These interactions may affect epitope accessibility

• Post-translational modifications:

  • SMYD2 itself may undergo modifications that alter antibody recognition

  • Different cell stimuli might affect these modifications

• Subcellular localization:

  • SMYD2 localizes to both cytoplasm and nucleus

  • Immunofluorescence staining should detect both nuclear and cytoplasmic patterns, and discrepancies may indicate antibody specificity issues

What controls should be included when evaluating SMYD2 antibody specificity?

Essential controls for evaluating SMYD2 antibody specificity:

• Genetic controls:

  • SMYD2 knockout cell lines or tissues (using CRISPR/Cas9 or siRNA)

  • SMYD2 conditional knockout systems (e.g., Smyd2 flox/flox crossed with Mx-1cre mice)

  • Verification of knockout by RT-qPCR, as shown in Supplementary Figures 2 and 3 for Smyd2 knockout mice

• Expression controls:

  • Overexpression of tagged SMYD2 (e.g., FLAG-SMYD2) to confirm antibody detection

  • Titration of recombinant SMYD2 protein in Western blot

  • Comparison with cells known to express varying levels of SMYD2

• Peptide competition:

  • Pre-incubation of antibody with the immunizing peptide should abolish specific signal

  • This confirms binding specificity to the intended epitope

• Cross-reactivity assessment:

  • Test against other SMYD family members (SMYD1, SMYD3, SMYD4, SMYD5)

  • Particularly important given the conserved SET and MYND domains

How can SMYD2 antibodies be used to investigate hematological malignancies?

SMYD2 antibodies are valuable tools for investigating hematological malignancies:

• Expression profiling:

  • SMYD2 is highly expressed in CML, MLLr-B-ALL, AML, T-ALL, and B-ALL leukemias

  • SMYD2 levels in B-ALL correlate with poor survival

  • Use Western blotting or immunohistochemistry with SMYD2 antibodies to assess expression levels in patient samples or cell lines

• Functional studies in leukemia models:

  • siRNA-mediated knockdown of SMYD2 in leukemia cell lines results in apoptosis

  • Measure caspase-3 activity and apoptosis following SMYD2 knockdown

  • Use SMYD2 antibodies to confirm knockdown efficiency (estimated at 75-80%)

• Target identification:

  • SMYD2 methylates multiple targets in leukemia cells

  • Combine immunoprecipitation with SMYD2 antibodies and mass spectrometry to identify novel substrates

  • Confirm methylation status using methyl-lysine-specific antibodies

What approaches can researchers use to study SMYD2's role in immune regulation?

To study SMYD2's role in immune regulation:

• Macrophage polarization studies:

  • SMYD2 is a negative regulator of macrophage activation and M1 polarization

  • Use SMYD2 antibodies to monitor expression changes during activation (SMYD2 expression decreases dramatically during LPS stimulation)

  • Combine with flow cytometry to assess surface markers like MHC-II, CD80, and CD40

• Cytokine production analysis:

  • Overexpression of SMYD2 in macrophages significantly suppresses TNF-α and IL-6 expression

  • SMYD2 knockdown increases TNF-α and IL-6 expression at both mRNA and protein levels

  • Use SMYD2 antibodies to confirm overexpression or knockdown efficiency

• T cell differentiation models:

  • Macrophages overexpressing SMYD2 suppress Th-17 cell differentiation but promote regulatory T cell differentiation

  • SMYD2 antibodies can be used to characterize the expression of SMYD2 in different immune cell populations

• Antiviral immunity research:

  • Smyd2-deficient mice are more resistant to viral infection by producing more IFN-I and proinflammatory cytokines

  • SMYD2 inhibits IRF3 phosphorylation in macrophages during viral infection

  • Use SMYD2 antibodies in combination with phospho-IRF3 antibodies to study this regulatory mechanism

How are SMYD2 antibodies being utilized in cardiovascular research?

SMYD2 antibodies in cardiovascular research applications:

• Vascular disease models:

  • SMYD2 expression is downregulated in injured carotid arteries in mice and phenotypically modulated VSMCs in vitro

  • Use immunofluorescence staining with SMYD2 antibodies to detect expression changes in vessel sections

  • Combine with smooth muscle cell markers like SM α-actin for co-localization studies

• VSMC phenotypic switching studies:

  • SMYD2 up-regulates VSMC contractile gene expression and suppresses VSMC proliferation and migration

  • SMYD2 promotes expression and transactivation of myocardin, a master transcription cofactor

  • Use SMYD2 antibodies in co-immunoprecipitation experiments to study interaction with myocardin

• Epigenetic regulation in vascular cells:

  • SMYD2 facilitates H3K4 methylation around SMC contractile gene promoters

  • Use ChIP with SMYD2 antibodies to examine recruitment to CArG regions of SMC contractile gene promoters

How can researchers effectively validate knockdown or knockout of SMYD2?

Effective validation of SMYD2 knockdown or knockout requires multiple approaches:

• Protein-level validation:

  • Western blotting with SMYD2 antibodies (typical dilution 1:1000)

  • Expected molecular weight: 49 kDa

  • Include positive control lysates from cells known to express SMYD2

• mRNA-level validation:

  • RT-qPCR using specific primers for Smyd2

  • Design primers spanning exon-exon junctions to avoid genomic DNA amplification

  • Example: verification of deletion in Smyd2 knockout mice by RT-qPCR as shown in Supplementary Figures 2 and 3

• Genomic validation for CRISPR-mediated knockout:

  • PCR amplification across the targeted region

  • Sequencing to confirm the presence of indels or desired mutations

  • For conditional systems, verify recombination efficiency using reporter genes (e.g., YFP LSL)

• Functional validation:

  • Assess changes in known SMYD2 methylation targets (p53K370me, H3K4me, H3K36me)

  • Examine phenotypic changes consistent with SMYD2 loss (e.g., increased apoptosis in leukemia cells )

What are the considerations for studying SMYD2 inhibitors using antibody-based techniques?

When studying SMYD2 inhibitors using antibody-based techniques, consider:

• Inhibitor specificity assessment:

  • Test inhibitors like BAY-598 with an IC₅₀ of 27 ± 7 nM against SMYD2

  • Verify >100-fold selectivity for SMYD2 over related enzymes like SMYD3

  • Use antibodies against known SMYD2 methylation targets to confirm on-target effects

• Monitoring cellular target engagement:

  • Use methyl-specific antibodies to detect reduction in SMYD2-mediated methylation of targets

  • Track changes in H3K36me2 at Tnf and Il6 promoters by ChIP-qPCR

  • Example: BAY-598 shows potent cellular activity, making it suitable for in vivo target validation studies

• Combining inhibitors with genetic approaches:

  • Compare inhibitor-treated cells with SMYD2 knockdown/knockout

  • Use SMYD2 antibodies to confirm that inhibitors do not affect protein levels, only activity

  • Include catalytically inactive SMYD2 mutants (Smyd2Y240A, Smyd2ΔNHSC, Smyd2ΔET, Smyd2ΔGED) as controls

• In vivo target engagement:

  • Use immunohistochemistry with SMYD2 antibodies to confirm expression in target tissues

  • Combine with antibodies against methylation marks to assess inhibitor efficacy in animal models

  • BAY-598 has appropriate DMPK properties for in vivo xenograft studies